Manufacturing related excipient videos!

Solving the Coating Process by Particle Counting

Which Tableting Process is right for you?

The Gamlen D-series Powder Compaction Analyzer in action

Reducing Formulation Risk with Science Based Excipient Selection - Thomas Durig

Process Videos Granulation & Pellet Coating

Role of Excipients in Design of Solid Amorphous Dispersions - Thomas Durig

Video on presentation by Ashland Inc., published Nov 7, 2014

Polymeric Drug Delivery Systems

Reliable Control of Fluidised Bed Coating

Fluid bed coating is used to improve drug release control, improve physical properties such as hardness and friability and to mask the unpleasant taste of some drug products. Monitoring particle size and distribution during the process ensures that the substrate is coated properly and evenly.

Innopharma Labs Eyecon Particle Characterizer technology enables customers to measure particle size and shape during a fluidised bed coating process. The Eyecon is a non-product contact instrument and can be fitted to pre-existing windows on most coating equipment, requiring no modification.

By monitoring the process in real-time using the Eyecon it is possible to examine the particle size growth profile over the duration of the coating process and thus determine the thickness of the coating applied. The ability to monitor particle growth at discreet time periods using the Eyecon allows for more in-depth understanding of the process and aids in the identification of process perturbations and enhanced process robustness.

Understanding of Fluid Bed Granulation with the Eyecon Particle Characteriser

Granulation is the process of agglomerating primary powder particles in order to produce larger aggregate granules. The process of granulation improves material properties such as flowability and compressibility and also avoids segregation of mixture components. There are two common methods of granulation, wet granulation and dry granulation.

Fluid bed granulation is a wet granulation process that involves the addition of a binder liquid to primary particles to form aggregated granulates. The material to be granulated is suspended within the fluid bed granulator by applying high velocity air across the particles in order to set-up a fluidised bed of material. The binder liquid is then sprayed upon the primary powder at a controlled addition rate which results in the particles adhering to each other and forming larger granulates. Upon completion of the spraying process the wet granulate is dried within the fluid bed granulator using hot air. During the spraying and drying process granulates will grow in size and then reduce due to inter granulate collisions which will cause attrition of the agglomerate.

The ability to monitor the granulate growth during binder addition and subsequent size reduction as a result of the drying process is possible with the integration of an Eyecon inline on a fluid bed granulator. The Eyecon allows for real-time monitoring of the granulation process which can be used to control and optimise critical process parameters such as binder addition rate, process length, drying time and the end point granulate size.

Optimelt - Hot Melt Extrusion Tecohnology

Joe Cobb Previews his 2012 AAPS Poster Presentation - QBD

2012 AAPS Poster Presentation


Joe Cobb and his team used the principles of QbD to improve the robustness of a core tablet for a novel modified release oral solid dosage form. For a preview of Joe's presentation, watch this short video about how Metrics applies the principles of QbD to solve formulation development issues.

Advil Tablet Manufacturing Process

Get More Scientific About Formulation!

CPhI Pharma Evolution


Paul Trusty, technical director of solid dosage forms at GSK, explains why pharma needs to catch up to other industries where materials science is concerned. A PhD, who once tested ingredients for Breyers ice cream, Paul is a materials scientist himself.


Accelerating to Phase I Clinical Trials for All Dosage Forms

Webinar PPD


This webinar discusses compounding at the Phase I clinic's pharmacy as a means to accelerate development and minimize CMC development resources. For more information, email us at, or visit us online at